Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.3501
Nov 20 • 3:59 PM ET Dollar change-0.0405 Percentage change(-10.37%)
Aftermarket Close
0.3699
Aftermarket • 7:07 PM ET Dollar change+0.0198 Percentage change(5.66%)
Index
-
Market Cap
47.66M
Enterprise Value
45.64M
Income
-29.90M
Sales
0.00M
Book/sh
-0.06
Cash/sh
0.02
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
29
IPO
Oct 05, 2001
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
19.61
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.89
Current Ratio
0.89
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-0.25
EPS next Y
-0.21
EPS next Q
-0.06
EPS this Y
-25.83%
EPS next Y
20.92%
EPS next 5Y
1.96%
EPS past 3/5Y
3.00% 6.32%
Sales past 3/5Y
- -
EPS Y/Y TTM
11.90%
Sales Y/Y TTM
-
EPS Q/Q
22.15%
Sales Q/Q
-
Insider Own
1.55%
Insider Trans
0.00%
Inst Own
10.75%
Inst Trans
-0.95%
ROA
-350.62%
ROE
-11838.99%
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-14.40%
SMA50
-34.75%
SMA200
-57.04%
Trades
Shs Outstand
132.21M
Shs Float
98.81M
52W High
1.30 -73.07%
52W Low
0.33 5.01%
Volatility
16.03% 11.92%
ATR (14)
0.05
RSI (14)
37.28
Beta
1.24
Rel Volume
0.96
Avg Volume
1.16M
Volume
1,108,678
Perf Week
-5.38%
Perf Month
-30.01%
Perf Quarter
-58.52%
Perf Half Y
-56.75%
Perf YTD
-59.94%
Perf Year
-64.69%
Perf 3Y
-77.98%
Perf 5Y
-79.88%
Perf 10Y
-81.34%
Prev Close
0.39
Price
0.35
Change %
-10.37%
Consensus
Strong Buy
Avg. Price Target
$4.48
Implied Upside
+1,179.6%
Analysts3incl. previous ratings
Rating Distribution3 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 13, 2025Initiated
LLake Street
Buy$7+1,899.4%
Oct 06, 2022Initiated
MMaxim Group
Buy$3+756.9%
Feb 17, 2021Initiated
HH.C. Wainwright
Buy$15+4,184.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parsons James T.DirectorMar 11 '26Buy1.0310,00010,30041,849Mar 13 08:00 AM
Kelly JaredChief Executive OfficerMar 12 '26Buy0.965,0504,848114,050Mar 13 08:00 AM
Kelly JaredChief Executive OfficerFeb 12 '26Buy0.8429,50024,839109,000Feb 13 07:00 AM
Kelly JaredChief Executive OfficerFeb 11 '26Buy0.845,6004,68279,500Feb 13 07:00 AM
Look KirkChief Financial OfficerFeb 12 '26Buy0.8412,00010,104287,515Feb 13 07:00 AM
Pisano WayneDirectorFeb 12 '26Buy0.8430,00025,338492,414Feb 13 07:00 AM
Heineman Thomas CharlesChief Medical OfficerFeb 12 '26Buy0.8312,13210,033282,818Feb 13 07:00 AM
Brown Deborah MargaretDirectorFeb 12 '26Buy0.8525,00021,240109,851Feb 13 07:00 AM
Hagerman AllisonVP, Product DevelopmentFeb 12 '26Buy0.8310,0008,298115,059Feb 13 07:00 AM
Seizinger Bernd R.DirectorFeb 11 '26Buy0.8360,00049,590526,991Feb 13 07:00 AM
Seizinger Bernd R.DirectorFeb 12 '26Buy0.8540,00033,864566,991Feb 13 07:00 AM
Aromando AndrewChief Business OfficerFeb 11 '26Buy0.8629,60025,41855,100Feb 13 07:00 AM
Andrews Patricia SDirectorFeb 12 '26Buy0.8635,40030,29278,128Feb 13 07:00 AM
Seizinger Bernd R.DirectorJan 16 '26Buy1.04100,000103,770466,991Jan 20 04:30 PM
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
L.L.M.Mr. Jared Kelly J.D.
CPAMr. Kirk J. Look C.A.
Ph.D.Dr. Thomas C. Heineman M.D.
Chief Operating OfficerMr. John McAdory
P.M.P.Ms. Allison Hagerman P.Eng.